

HEALTH POLICY

Increasing Access to Medications for Opioid Use Disorder in Primary Care: Removing the Training Requirement May Not Be Enough

Holly Ann Russell, MD, MS, Mechelle Sanders, PhD(c), Jessica K. V. Meyer, Elizabeth Loomis, MD, Teraisa Mullaney, MS, PhD, and Kevin Fiscella, MD, MPH

Background: Substance use disorders, including opioid use disorder (OUD), are understood as chronic diseases with a relapsing and remitting course and no known cure. Medications for OUD (MOUD) are well established with decades of evidence supporting their safety and efficacy; however, treatment access remains poor and inequitable. Buprenorphine is an MOUD that can be prescribed in a primary care outpatient setting, although regulatory and administrative challenges are a barrier to prescribing it. Recent regulatory changes offer an opportunity to expand the number of family doctors who treat OUD.

Methods: We offered free, easily accessible buprenorphine “x-waiver training” led by a team of primary care clinicians. In addition, we provided wrap-around support for MOUD clinical questions and administrative needs with experienced family medicine mentors.

Results: More than 400 clinicians attended our trainings, including medical students, residents, and attending physicians. Of the 101 attending physicians who completed our trainings, only 30 went on to apply for an x-waiver, and of those only 7 were currently prescribing when contacted 12 months later.

Conclusion: Our experience indicates that removing the training requirement is a necessary first step but is unlikely to result in major changes to rates of prescribing without other significant cultural changes. (J Am Board Fam Med 2021;34:1212–1215.)

Keywords: Access to Health Care, Buprenorphine, Continuing Medical Education, Family Medicine, Family Physicians, Health Policy, Opioid-Related Disorders, Opioids, Primary Health Care

Introduction

Although definitions of chronic disease differ between the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO), and many other groups, some experts argue for using the simplest description defining chronic disease as “continuing or occurring again and again

for a long time.”¹ As our understanding of substance use disorders (SUDs) and in particular opioid use disorder (OUD) increases, these conditions are widely considered to fall within the umbrella of chronic disease. OUD is heritable, is characterized by relapsing and remitting patterns of severity, has significant morbidity and mortality if untreated, and has no “cure.”² Family medicine, with our history of patient-centered care and team-based, longitudinal disease management, serves as an ideal setting for long-term management of OUD. With COVID-19 we see a “dual pandemic” with never-before-seen rates of opioid overdoses and an even greater need to expand access to treatment.

There are 3 Food and Drug Administration (FDA)-approved, evidenced-based medications for

This article was externally peer reviewed.
Submitted 18 May 2021; revised 26 August 2021; accepted 30 August 2021.

From the Department of Family Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY (HAR); Department of Family Medicine, United Memorial Medical Center, Batavia, NY (EL); Department of Family Medicine, University of Rochester Medical Center, Rochester, NY (MS, KF); University of Rochester School of Medicine and Dentistry, Rochester, NY (TM, JKVM).

Funding: This project was supported by a grant from the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number T0BHP28587 Medication-Assisted Treatment in Opioid Use Disorders.

Conflict of interest: The authors report no conflict of interest.

Corresponding author: Holly Russell, MD, 777 South Clinton Ave, Suite 400, Rochester, NY 14620 (E-mail: Holly_russell@urmc.rochester.edu).

OUD (MOUD), including opioid agonists (methadone and buprenorphine) and opioid antagonists (naltrexone). Decades of evidence in different settings and populations show that buprenorphine and methadone decrease the risk of opioid overdose death. Recent evidence confirms that treatment with medication should be first line as compared with more traditional nonpharmacologic behavioral health and counseling approaches.³ The DATA 2000 law⁴ allowed a new opportunity for office-based treatment of OUDs using buprenorphine if the physician met several criteria, most notably attending an 8-hour training course.⁵

Only a small fraction of US primary care physicians (PCPs) have their “x-waiver” and even fewer of those with the waiver go on to prescribe MOUD. The American Academy of Family Physicians (AAFP), in a position article,⁶ details the barriers to prescribing MOUD and commits to working to reduce these barriers to increase the number of family physicians who treat OUD in their office. Commonly cited barriers to obtaining the waiver and prescribing buprenorphine include lack of training and mentors, fear of a Drug Enforcement Administration (DEA) audit, and lack of time and money to integrate these services into busy primary care offices.^{7,8}

Methods

In 2018, our program received a grant to increase the number of locally waived clinicians by addressing these barriers. We provided free, conveniently located buprenorphine waiver training by a team of primary care clinicians with office-level administrative support to implement buprenorphine prescribing and mentoring with experienced clinicians⁹ once a waiver was obtained.

We used the American Society of Addiction Medicine (ASAM) and later the Provider Clinical Support System (PCSS) trainings when it became free to use. We received approval from both agencies to slightly modify their slides to add local data and include cases specifically directed to a primary care audience. We included anecdotes about our own personal experience with prescribing buprenorphine since 2014, including how we managed after-hours calls, challenging case scenarios, note writing, and billing. Many of our trainings were directed at primary care residents (including family medicine, internal medicine, and OB/GYN) as well as medical

students. Since residents do not generally have their own DEA license, they cannot apply for the buprenorphine “x-waiver” until they graduate. In addition, many advance practice providers (APPs) participated but until recently needed to complete 16 hours of additional training. Thus, we excluded APPs, residents, and medical students from this evaluation as they were not able to prescribe buprenorphine at the end of the training.

Results

In a period of 3 years, approximately 400 individuals participated in 17 different waiver trainings led by our team. Of the 101 attending physicians who attended our trainings, only 30 went on to apply for an x-waiver, and of those only 7 were currently prescribing when contacted 12 months later (see Table 1 and Table 2 for details and breakdown by specialty).

Table 1. Attending Physician Participants

	Participated	
		%
Total	101	100%
MD	86	85%
MD, MPH	3	3%
DO	12	12%
Medically underserved*	38	38%
Rural*	22	22%
Specialty		
FM	24	24%
IM	23	23%
OB/GYN	19	19%
EM	17	17%
EM/FM	1	1%
PSY	8	8%
MED/PED	5	5%
SUR	2	2%
ANT	1	1%
PED	1	1%
Waiver		
Yes	27	27%
Applied	3	3%
Plans to Apply	4	4%
Maybe	1	1%
No	13	13%
Took course for knowledge	1	1%
Moving out of NY	1	1%
Unknown/no response	39	39%

*Not all participants reported.

Table 2. Attending Physician Participants Who Applied for Buprenorphine “x-Waiver”

		Waiver [†]	
		% of Waiver (n = 30)	% of Participating (n Variable)
Total	30	100%	30%
MD	26	87%	30%
MD, MPH	1	3%	33%
DO	3	10%	25%
Medically underserved*	13	43%	34%
Rural*	6	20%	27%
Currently prescribing [‡]	7	23%	NA
Specialty			
FM	9	30%	38%
IM	7	23%	30%
OB/GYN	4	13%	21%
EM	5	17%	29%
EM/FM	0	0%	0%
PSY	1	3%	13%
MED/PED	3	10%	60%
SUR	0	0%	0%
ANT	0	0%	0%

*Not all participants reported.

[†]Waiver = yes/applied.

[‡]As of last contact 12 months from training.

Discussion

Our results are consistent with what is found in other programs,¹⁰ but we find them disappointing. Our program was designed to explicitly address the barriers noted in the literature, and yet only 7 clinicians went on to actively prescribe. The Trump administration issued an end-of-term announcement that the waiver was to be eliminated;¹¹ however, this was quickly withdrawn by the Biden administration due to “significant legal and clinical concerns.”¹² A new announcement allows an exemption for practitioners who are licensed under state law and who possess a valid DEA registration to submit a notice of intent (NOI) to prescribe buprenorphine with a patient limit of 30 *without* certifying to any additional training.¹³ Medical experts have noted that this requirement for additional training is unique to buprenorphine and is not required for other, much more dangerous medications.¹⁴

We believe our experience provides further evidence that there are multiple levels of complex barriers to increasing access to MOUD in primary care. The most commonly cited reasons for not pursuing a waiver or actively prescribing among our participants was that clinicians did not see a

need in their practice or that the opportunity had not arisen to prescribe. Our findings may be understood in the context of the capability, opportunity, motivation, and behavior model (COM-B).¹⁵ According to COM-B, a person’s capability, opportunity, and motivation influence whether they carry out a behavior. While our training addressed the capability (eg, waiver training), it did not address the opportunity and motivation to prescribe.

The ability to intervene on opportunity and motivation are complicated barriers that likely relate to discomfort with the unknown, pervasive stigma against people with SUDs, and concerns about administrative and legal regulations. Studies of PCPs and SUD treatment facilities have shown low understanding of effectiveness and at times active discouragement of the use of MOUDs.^{16,17} Adherence to or greater familiarity with a more traditional 12-step approach to treatment is negatively associated with acceptability of MOUD.¹⁸ In addition, there are regional differences in acceptability, education, and training. The direct experience of seeing OUD treatment successfully implemented in a primary care clinic may be the most efficient way to increase opportunity and motivation.^{19,20}

We believe that removing the requirement for additional training is an important first step in increasing access to long-term OUD treatment. However, equally important is normalizing the prescribing of buprenorphine in primary care settings and creating opportunities for clinicians at all levels of training to have direct experience seeing patients receive MOUD in a primary care setting. If the requirement is removed and clinicians are not motivated to obtain waivers, are not clear on the safety or effectiveness of MOUDs, or do not screen for opportunities to use them, then impact on access will be minimal.

Starting in undergraduate medical education, we must include instruction about the chronic disease model of SUD, expand interventions to decrease clinician-based stigma, and implement strategies to build trust around disclosure with patients in a primary care setting and better ways to screen for patient need and acceptance of treatment from a PCP. This is a cultural change in the way that substance use has traditionally been treated, and patients may not know, or may not trust, that they will receive adequate treatment in this setting. We need to educate *both* providers and patients that primary care is the right place

for long-term treatment similar to diabetes and hypertension.

Conclusion

National reforms that support having primary care access to substance use counselors and/or OUD care coordinators along with permanent removal of barriers and continuous medical education will help improve uptake and access to pharmacotherapy for OUD. Ultimately, however, cultural change in primary care toward OUD will be achieved through provider-to-provider conversations and exposure to the transformative experiences of treating OUD in primary care.

The authors wish to thank Kathleen Silver for assistance with managing the training program and manuscript preparation.

To see this article online, please go to: <http://jabfm.org/content/34/6/1212.full>.

References

1. Bernell S, Howard SW. Use your words carefully: what is a chronic disease? *Front Public Health* 2016;4:159.
2. Saitz R, Larson MJ, Labelle C, Richardson J, Samet JH. The case for chronic disease management for addiction. *J Addict Med* 2008;2:55–65.
3. Wakeman SE, Larochelle MR, Ameli O, et al. Comparative effectiveness of different treatment pathways for opioid use disorder. *JAMA Netw Open* 2020;3:e1920622.
4. Mancher M, Leshner AI, (Editors). Medications for opioid use disorder save lives. Washington (DC): National Academies Press; 2019.
5. Substance Abuse and Mental Health Services Administration (SAMHSA). Become a buprenorphine waived practitioner. US Department of Health & Human Services; May 4, 2021. Available from: <https://www.samhsa.gov/medication-assisted-treatment/become-buprenorphine-waivered-practitioner>. Accessed May 5, 2021.
6. American Academy of Family Physicians. Chronic pain management and opioid misuse: a public health concern (position paper). 2016.
7. DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA, Jr. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. *Rural Remote Health* 2015;15:3019.
8. Hutchinson E, Catlin M, Andrilla CH, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. *Ann Fam Med* 2014;12:128–33.
9. Loomis L, Hayes A, Russell HA. Overcoming barriers to treatment of opioid use disorder in primary care. *Family Doctor* 2020;8:31–4.
10. Kunins HV, Sohler NL, Giovanniello A, Thompson D, Cunningham CO. A buprenorphine education and training program for primary care residents: implementation and evaluation. *Subst Abus* 2013;34:242–7.
11. US Department of Health and Human Services. HHS expands access to treatment for opioid use disorder; January 14, 2021. Available from: <https://www.hhs.gov/about/news/2021/01/14/hhs-expands-access-to-treatment-for-opioid-use-disorder.html>. Accessed May 5, 2021.
12. Diamond D, Bernstein L. Biden moving to nix Trump plan on opioid-treatment prescriptions. *Washington Post*; January 25, 2021. Available from: <https://www.washingtonpost.com/health/2021/01/25/biden-buprenorphine-waiver/>. Accessed May 5, 2021.
13. Office of the Secretary, Department of Health and Human Services. Practice guidelines for the administration of buprenorphine for treating opioid use disorder; April 28, 2021. Available from: <https://www.federalregister.gov/documents/2021/04/28/2021-08961/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder>. Accessed May 5, 2021.
14. Fiscella K, Wakeman SE, Beletsky L. Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: the X waiver. *JAMA Psychiatry* 2019;76:229–30.
15. Michie S, Atkins L, West R. The behaviour change wheel: a guide to designing interventions. Sutton, Surrey: Silverback Publishing; 2014.
16. Beetham T, Saloner B, Gaye M, Wakeman SE, Frank RG, Barnett ML. Therapies offered at residential addiction treatment programs in the United States. *JAMA* 2020;324:804–6.
17. McGinty EE, Stone EM, Kennedy-Hendricks A, Bachhuber MA, Barry CL. Medication for opioid use disorder: a national survey of primary care physicians. *Ann Intern Med* 2020;173:160–2.
18. Aletraris L, Edmond MB, Paino M, Fields D, Roman PM. Counselor training and attitudes toward pharmacotherapies for opioid use disorder. *Subst Abus* 2016;37:47–53.
19. James JR, Marolf M, Klein JW, Blalock KL, Merrill JO, Tsui JL. Staff attitudes toward buprenorphine before and after implementation of an office-based opioid treatment program in an urban teaching clinic. *Subst Use Misuse* 2021;56:1569–75.
20. Pytell JD, Buresh ME, Graddy R. Outcomes of a novel office-based opioid treatment program in an internal medicine resident continuity practice. *Addict Sci Clin Pract* 2019;14:46.